Additional Nodal Metastasis Nomogram

ورودی‌های بالینی بیمار

حداقل ۰ — حداکثر ۱۴

حداقل ۰ — حداکثر ۷

حداقل ۰ — حداکثر ۹ • واحد: cm

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
probability
—%
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Very Low Risk0–10
  • Low Risk10–20
  • Moderate Risk20–50
  • High Risk50–100
Direct Clinical Answer

The Additional Nodal Metastasis Nomogram calculates predicting probability of additional non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy. Key inputs include nuclear grade. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. Routine clinical application promotes standardized evidence-based patient management.

Clinical Guidelines & Evidence

Predicts probability of additional non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy

Clinical Indication

The Additional Nodal Metastasis Nomogram is indicated for bedside clinical practice to support Predicts probability of additional non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.

Formula & Variables:

Linear predictor = β₀ + β₁(nuclear grade) + β₂(LVI) + β₃(multifocal) + β₄(ER status) + β₅(negative SLNs) + β₆(positive SLNs) + β₇(pathologic size) + β₈(detection method). Probability = exp(linear predictor) / (1 + exp(linear predictor))

Input Parameters

NameTypeRequiredDescription
nuclear_gradestringYesNuclear grade and tumor type
lymphovascular_invasionstringYesPresence of lymphovascular invasion (LVI)
multifocalstringYesMultifocal tumor (cancer in multiple locations in breast)
estrogen_receptor_statusstringYesEstrogen receptor (ER) status
negative_slnsintegerYesNumber of negative sentinel lymph nodes
positive_slnsintegerYesNumber of positive sentinel lymph nodes
pathologic_sizefloatYesPathologic size of tumor in centimeters(cm)
detection_methodstringYesMethod of detection of sentinel lymph node metastases

Score Interpretation & Guidance

RangeStageDescription
0–10Very Low RiskVery low probability
10–20Low RiskLow probability
20–50Moderate RiskModerate probability
50–100High RiskHigh probability

Evidence-Based References (EBM)

  • Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, Tan LK, Borgen PI, Cody HS 3rd, Kattan MW. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003 Dec;10(10):1140-51.
  • Specht MC, Kattan MW, Gonen M, Fey J, Van Zee KJ. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol. 2005 Aug;12(8):654-9.

Related calculators